Search results
Showing 631 to 645 of 2026 results for nice guidelines
Myocardial infarction: medication for MI more than 12 months ago (IND126)
This indicator covers the percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel, or anticoagulant drug therapy) and a statin, and a beta-blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM80
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers...
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers...
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.
Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.
This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.
How to register as a stakeholder with NICE.
How to register as a stakeholder with NICE.
{"@type":"ListItem","position":3,"item":{"name":"Podcasts"}}]} Podcasts Our NICE talks podcasts bring you the real life experiences of...